News | June 08, 2024
GSK acquires oligonucleotide drug startup Elsie
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
Merck has opened its newly expanded Life Science distribution center in Schnelldorf, Germany
Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer and GSK will continue to vigorously defend itself against all claims
Sleep disturbances are among the most frequent and disruptive symptoms associated with menopause which can impact women’s health and quality of life
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Launch of 20 new medicines expected by 2030
Subscribe To Our Newsletter & Stay Updated
